University of Hertfordshire

Role of prostacyclin in pulmonary hypertension

Research output: Contribution to journalArticle

Documents

  • 907160

    Final published version, 381 KB, PDF document

  • Jane A. Mitchell
  • Blerina Ahmetaj-Shala
  • Nick Kirkby
  • William R. Wright
  • Louise Susan MacKenzie
  • Dan Reed
  • Nura Mohamed
View graph of relations
Original languageEnglish
Article number53
Number of pages12
JournalGlobal Cardiology Science and Practice
Journal publication date31 Dec 2014
Volume2014
Issue4
DOIs
Publication statusPublished - 31 Dec 2014

Abstract


Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it’s discovery in the 1980s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses these and other issues relating to prostacyclin and its use in pulmonary arterial hypertension

Notes

Date of Acceptance: 11/12/2014 This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

ID: 7929880